Consensus estimates for the third quarter of 2026 project zero revenue and an EPS loss of $0.31, while the current stock price of $19.56 trades at a significant discount to the average analyst target of $42.89.
The primary focus for investors remains the initiation timeline for the GH001 global Phase 3 pivotal program in treatment-resistant depression, following the resolution of the FDA clinical hold earlier this year.
Analysts are seeking confirmation that pivotal trial enrollment is on track for a late 2026 start. Additionally, investors will scrutinize the company’s cash burn rate to ensure the current liquidity position remains sufficient to fund operations through critical clinical readouts in 2027.